Back to Search
Start Over
Antioxidant compounds of Kielmeyera coriacea Mart. with α-amylase, lipase and advanced glycation end-product inhibitory activities.
- Source :
-
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2021 Nov 30; Vol. 206, pp. 114387. Date of Electronic Publication: 2021 Sep 20. - Publication Year :
- 2021
-
Abstract
- Chronic hyperglycemia and hyperlipidemia are associated with excessive formation of reactive oxygen species and advanced glycation end-products. The present study aimed to evaluate the potential in vitro antidiabetic properties of Kielmeyera coriacea inner bark. The main phytochemical compounds were identified by UHPLC-ESI/MS <superscript>n</superscript> and the ethanol extract and its fractions were used to evaluate their antioxidant and anti-glycation capacities, as well as their inhibitory potential against glycoside and lipid hydrolases activities. The polar fractions, especially the n-butanol fraction, had free radical scavenging and quenching properties (ORAC and FRAP values>1800 and 1000 µmol trolox eq/g, respectively, and DPPH IC <subscript>50</subscript> <4 µg/mL), and inhibited ROS production (p < 0.01), lipid peroxidation (p < 0.001), glycation (IC <subscript>50</subscript> ~ 10 µg/mL in the BSA-fructose assay; IC <subscript>50</subscript> ~ 200 µg/mL in the BSA-methylglyoxal and arginine-methylglyoxal assays), α-amylase (IC <subscript>50</subscript> <0.1 µg/mL) and lipase (IC <subscript>50</subscript> <5 µg/mL), with no cytotoxicity. Biomolecules well-known as potent antioxidants were identified for the first time in the inner bark of K. coriacea, such as protocatechuic acid, epicatechin and procyanidins A, B and C. Together, our results support the antioxidant, anti-glycation and glycoside and lipid hydrolases inhibitory properties of the inner bark of K. coriacea, a species found in the Brazilian savanna, which makes it especially useful to combat oxidative stress and hyperglycemia and hyperlipidemia.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2021 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1873-264X
- Volume :
- 206
- Database :
- MEDLINE
- Journal :
- Journal of pharmaceutical and biomedical analysis
- Publication Type :
- Academic Journal
- Accession number :
- 34583125
- Full Text :
- https://doi.org/10.1016/j.jpba.2021.114387